Three CECRs receive $4 million from Merck Canada

Guest Contributor
April 24, 2013

Merck Canada is investing $4 million in three Centres of Excellence for Commercialization and Research (CECR) as part of a $100-million commitment it made in 2010 when it closed its Merck Frosst Centre for Therapeutic Research in a global restructuring (R$, July 19/10). The funding goes to the Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR) in Montreal, MaRS Innovation in Toronto and the Centre for Drug Research and Development in Vancouver. The Merck investment brings its investments since closing its centre for therapeutic research to $65 million. It is reflective of the firm's new R&D business model emphasizing partnerships to accelerate drug development and commercialization….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.